Literature DB >> 19294418

Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma.

Xin-Da Zhou1, Zhao-You Tang, Jia Fan, Jian Zhou, Zhi-Quan Wu, Lun-Xiu Qin, Zeng-Chen Ma, Hui-Chuan Sun, Shuang-Jian Qiu, Yao Yu, Ning Ren, Qing-Hai Ye, Lu Wang, Sheng-Long Ye.   

Abstract

PURPOSE: To clarify clinicopathologic differences between patients with intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC), and identify potential factors influencing survival after hepatectomy for ICC.
METHODS: Comparison of clinicopathologic data was made between patients who underwent hepatectomy for ICC (n = 272) and HCC (n = 5,829) during the same period. Twenty-five clinicopathologic variables were selected for univariate and multivariate analyses to evaluate their influence on prognosis of ICC.
RESULTS: Compared with patients with HCC, ICC patients were more common in females and more elderly, had a lower proportion of asymptomatic tumors, lower serum alpha-fetoprotein, higher serum carcinoembryonic antigen, carbohydrate antigen 19-9 and alkaline phosphatase levels; lower incidence of hepatitis history, associated cirrhosis and serum hepatitis B surface antigen; lower proportion of small tumors, well-encapsulated tumors and tumor emboli in the portal vein; higher proportion of single tumor, perihila lymph node involvement and poor differentiation; and less frequency of limited resection (all, P < 0.0001). Distant metastasis was less frequent in patients with ICC (P = 0.027). A total of 5-years overall and disease-free survival (in brackets) after resection was 26.4% (13.1%) and 44.5% (33.1%) (P < 0.0001, P < 0.0001) for patients with ICC and HCC, respectively. Factors influencing survival after resection of ICC can be divided mainly into two categories: early detection of asymptomatic ICC (P < 0.0001) and curative resection (P = 0.002).
CONCLUSION: ICC Patients have distinct clinicopathologic features as compared with HCC patients. Surgery remains the only effective treatment for ICC. Early detection of asymptomatic ICC and curative resection were the key to achieve optimal survival.

Entities:  

Mesh:

Year:  2009        PMID: 19294418     DOI: 10.1007/s00432-009-0547-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Clinical experience in 20 hepatic resections for peripheral cholangiocarcinoma.

Authors:  M F Chen; Y Y Jan; C S Wang; L B Jeng; T L Hwang
Journal:  Cancer       Date:  1989-12-01       Impact factor: 6.860

3.  Liver transplantation for cholangiocarcinoma: results in 207 patients.

Authors:  C G Meyer; I Penn; L James
Journal:  Transplantation       Date:  2000-04-27       Impact factor: 4.939

4.  A western surgical experience of peripheral cholangiocarcinoma.

Authors:  S V Berdah; J R Delpero; S Garcia; J Hardwigsen; Y P Le Treut
Journal:  Br J Surg       Date:  1996-11       Impact factor: 6.939

5.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

6.  Surgery for large primary liver cancer more than 10 cm in diameter.

Authors:  Xin-Da Zhou; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Jia Fan; Lun-Xiu Qin; Bo-Heng Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-30       Impact factor: 4.553

7.  Minute nodular intrahepatic cholangiocarcinoma.

Authors:  M Yamamoto; K Takasaki; M Nakano; A Saito
Journal:  Cancer       Date:  1998-06-01       Impact factor: 6.860

8.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

9.  Clinical characteristics and proliferating activity of intrahepatic cholangiocarcinoma.

Authors:  K Ohashi; Y Nakajima; M Tsutsumi; H Kanehiro; T Fukuoka; M Hisanaga; J Taki; D Nakae; Y Konishi; H Nakano
Journal:  J Gastroenterol Hepatol       Date:  1994 Sep-Oct       Impact factor: 4.029

10.  Surgical treatment of cholangiocellular carcinoma.

Authors:  R Pichlmayr; P Lamesch; A Weimann; G Tusch; B Ringe
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  31 in total

1.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

2.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

Review 3.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review.

Authors:  Neda Amini; Aslam Ejaz; Gaya Spolverato; Shishir K Maithel; Yuhree Kim; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-10-10       Impact factor: 3.452

Review 5.  Surveillance for hepatocellular carcinoma.

Authors:  Jeyamani Ramachandran
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 6.  The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Vivek A Saraswat; Anil Arora; Ajay Duseja; Mahesh K Goenka; Deepali Jain; Premashish Kar; Manoj Kumar; Vinay Kumaran; Kunisshery M Mohandas; Dipanjan Panda; Shashi B Paul; Jeyamani Ramachandran; Hariharan Ramesh; Padaki N Rao; Samir R Shah; Hanish Sharma; Ragesh B Thandassery
Journal:  J Clin Exp Hepatol       Date:  2014-05-22

7.  Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma.

Authors:  Zhen-Feng Wu; Xiao-Yu Wu; Nan Zhu; Zhe Xu; Wei-Su Li; Hai-Bin Zhang; Ning Yang; Xue-Quan Yao; Fu-Kun Liu; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 8.  Surgical outcomes of intrahepatic cholangiocarcinoma.

Authors:  Masakazu Yamamoto; Shun-ichi Ariizumi
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

9.  Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study.

Authors:  Xu-Feng Zhang; Jeffery Chakedis; Fabio Bagante; Eliza W Beal; Yi Lv; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

Review 10.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.